French drugmaker delivers first semi-synthetic malaria drugs

Credit: CDC

French pharmaceutical giant Sanofi announced Tuesday the delivery of the first anti-malaria drugs using a semi-synthetic version of their key ingredient to millions of patients in Africa.

Sanofi said that the development of semi-synthetic artemisinin—the weapon of choise against malaria—signalled a "new era" in the fight against the mosquito-borne disease.

Artemisinin is normally derived from a plant called sweet wormwood, but the weather can affect harvests of the plant, causing shortages and .

The drugmaker said it had been able to make 1.7 million treatments with the semi-synthetic alternative, which will be shipped to Burkina Faso, Burundi, Democratic Republic of the Congo, Liberia, Niger, and Nigeria in the coming months.

The World Health Organization gave the use of semi-synthetic artemisinin in malaria products the in May last year.

Sanofi said that "by complementing botanically-derived supplies, the new option can widen access to treatment for millions sickened by malaria every year."

According to the WHO's last malaria report, published last December, the disease killed 627,000 people in 2012, mainly children in Africa, with an estimated 207 million cases worldwide.

add to favorites email to friend print save as pdf

Related Stories

Antimalarial drug artemisinin moves into production

Jul 12, 2010

(PhysOrg.com) -- A semi-synthetic version of the antimalarial drug artemisinin developed by UC Berkeley's Jay Keasling is moving out of development into full-scale production, helped along by a $10.7 million grant from the ...

Lab boost for precious anti-malaria drug

Apr 10, 2013

US scientists on Wednesday said they had used baker's yeast to make a key ingredient of malaria drugs, a feat that could iron out fluctuations in supply caused by sourcing the chemical from a Chinese herb.

Recommended for you

Xtoro approved for swimmer's ear

23 hours ago

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

Drug interaction identified for ondansetron, tramadol

23 hours ago

(HealthDay)—In the early postoperative period, ondansetron is associated with increased requirements for tramadol consumption, according to a review and meta-analysis published online Dec. 10 in Anaesthesia.

New system targets germs in donated blood plasma

Dec 17, 2014

(HealthDay)—A new system designed to eliminate germs in donated blood plasma and reduce the risk of transmitting a plasma-borne infection has been approved by the U.S. Food and Drug Administration.

Judge halts Alzheimer's drug swap until July

Dec 16, 2014

A federal judge has ordered an Irish drug manufacturer to halt its plans to discontinue its widely used Alzheimer's medication, allegedly in an effort to drive patients to a newer patented drug.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.